

UNIVERSITY OF KANSAS SCHOOL OF MEDICINE
OSSAMA W. TAWFIK, M.D., PH.D.
Professor
Department of Pathology and Laboratory Medicine
Vice-Chairman for Education and Outreach
Director of Anatomic and Surgical Pathology
FACULTY CURRICULUM VITAE

A. Name: Ossama William Tawfik **Department:** Pathology and Lab Medicine

B. Personal Data:

Office Address and Phone

1615 Bell Hospital
Department of Pathology & Laboratory Medicine
Kansas University Med Center (KUMC)
3901 Rainbow Blvd.
Kansas City, Kansas 66160
(913) 588-1185 (work)
(913) 588-8780 Fax
otawfik@kumc.edu

Professional Registration/Licensure:

State

1. Kansas
2. Egypt

C. Education:

<u>Year</u>	<u>Degree</u>	<u>Institution</u>
1978	MBBCh (MD)	Cairo University, Egypt
1987	PhD	KUMC

D. Postgraduate Education:

<u>Year</u>	<u>Degree</u>	<u>Institution</u>
1980	Internship	Cairo University, Egypt
1981	Clinical Pathology resident	Cairo University, Egypt
1982	Fellow	KUMC and Community Blood Center

1987	Post Doctoral Fellow	KUMC (Obstetrics and Gynecology- OB/GYN)
1988-91	Anatomic & Clinical Pathology Resident	KUMC (Pathology)
1992	Surgical Pathology Fellow	KUMC

E. Academic Appointments:

<u>Month and Year</u>	<u>Position</u>	<u>Institution</u>
12/1992	Assistant Prof	KUMC (Pathology)
2/1996	Clin Assist Prof	KUMC (OB/GYN)
7/1998	Associate Prof	KUMC (Pathology, OB/GYN)
7/1998	Associate Prof	University of Kansas Health Sciences Graduate School
7/2003	Professor	KUMC (Pathology, OB/GYN) and Graduate School

F. Certification:

	<u>Year</u>
ECFMG	1988
FLEX	1992
American Board of Pathology	
"Board Diplomate in Anatomic and Clinical Pathology"	June 1993
"Board Diplomate in Cytopathology"	July 1997

G. Professional Societies and Affiliations: (Including offices held)

<u>Year</u>	<u>Organization</u>	<u>Office</u>
1991-present	College of American pathologists	
1991-present	American Society of Clinical Pathologists	
1992-present	US and Canadian Academy of Pathologists	
1988-present	Kansas City Society of Pathologists	President elect (2001) Treasurer (2000) Past president (2002)
1994-present	Arab American Medical Association, Kansas Chapter	Secretary (1997-1998) Treasurer (1998-1999) President elect (1999-2000) CME chair (1998-2004)
1998-present	American Society of Cytology	
1998-present	Anatomic Pathology Director and Surgical pathology Directors Association	
1999-present	Gynecologic Oncology Group (GOG)	
1999-present	Children's Oncology Group (COG)	

2000-present	International Urologic Pathology Society
2003-present	Arthur Purdy Stout Society of Surgical Pathologists
2003-present	Kansas Society of Pathologists

H. Honors and Awards: (Include services on national and international professional committees, study sections, offices in professional societies, membership of editorial Boards, positions as reviewer for scientific journals, Etc.)

1972 - 1978	Medical School scholarship
1978	Graduated from Medical School with honors
1982 - 1984	Peace fellowship award to USA, KUMC
1985	Travel award, Department of Graduate Studies, KUMC
1986	Travel award, Department of Graduate Studies, KUMC
1991-1994	Member of the College of American Pathologists/American Fertility Society Reproductive Biology Resource Committee.
1997	Secretary, Arab American Medical Association (AAMA), Kansas Chapter
1998	Treasurer, AAMA, Kansas Chapter
1999	President elect, AAMA, Kansas Chapter
1998	Helmut A Sprintz' Excellence in Teaching Award, Department of Pathology & Laboratory Medicine, KUMC
1999	Helmut A Sprintz' Excellence in Teaching Award, Department of Pathology & Laboratory Medicine, KUMC
2000	Award for excellence in leadership and service commitment Kansas Chapter of the Arab American Medical Association
2000-2004	Editorial Board for the Journal of Urologic Pathology
2000	President, Kansas City Society of Pathologists
2001	Strathmore's Who's Who
2002	American's Registry of outstanding professionals
2002	National AAMA as the best organizer of CME meetings award
2003	Member of the Arthur Purdy Stout Society of Surgical Pathologists
2002	Academic consultant, ChromaVision, Automated Cellular Imaging System Co.
2002	KU MED Hospital Executive Committee
2003	Surgical pathology Task Force Award
2003	Helmut A Sprintz' Excellence in Teaching Award, Department of Pathology & Laboratory Medicine, KUMC
2004	Certificate of Excellence, chair of school of medicine research committee And executive committee of KU School of Medicine, KUMC
2004	Consulting Editor of the Contemporary Who's Who, American Biographic Institute
2007	Member of the Diagnostic Immunology Resource Committee, American College of Pathologists

I. Research Activities:

1. *Area of research interests:*

- A. *Tumor Biology*
**BREAST, PROSTATE, GYN AND GU MALIGNANCIES
MELANOMA IMMUNOTHERPY AND VACCINATION
TUMOR BIOMARKERS
CLINICAL TRIALS EXPERIENCE FOR OVER 10 YEARS IN
CHEMOPREVENTION STUDIES**
- B. *Atherosclerosis*
- C. *Immunobiology of Endometriosis:*
- D. *Intestinal Transplant Biology*
- E. *Image Analysis*
- F. *Telepathology*

3. *Grant support available:*

- a) Previous grants:
Departmental start up funds (\$50,000.00) for 3 years

Phase 2 Clinical Trial - Agent in Breast Dysplasia with Biomarkers Abnormalities.

Project period: 7/98-7/2000
Amount: \$1,425,932
Source of support: NCI
Investigators: C Fabian, MD (PI), Tawfik, MD, PhD (Co-investigator)
Dr Tawfik's % effort 5%

Chemoprevention for Women at High Risk of Breast Cancer

Project Period: 9/1/97-8/31/2002
Amount: \$3,912,748
Source of support: NCI
Investigators: C Fabian, MD (PI), Tawfik, MD, PhD (Co-investigator), et al.
Dr Tawfik's % effort 5%

Phase 2 Clinical Study of Predictive Image Analysis Features in Prostate cancer

Project period: 12/1/98-12/1/2000
Amount: 176,786 (KU only)
Source of support NCI and University of Alabama
Investigators: Ossama Tawfik, MD, PhD (**Principal Investigator**)

In collaboration with the University of Alabama at Birmingham
Dr Tawfik's % effort 20% as PI at KU

Autologous Tumor cells Transduced Ex Vivo with Adenovirus Vector

Project period 1 year 3/21/2001 – 3/20/2002
Amount: \$35,000
Source of support KUMC-RI
Investigators: S Williamson, MD, Tawfik, MD, PhD (Co-investigator), et al.
Dr Tawfik's % effort 5%

A Phase I NonRandomized Multiple-Dose Safety, Pharmacokinetic, and Pharmacodynamic (Biomarker modulation) Study of an Antiestrogen in Women with Newly-Diagnosed Breast Cancer

Project period: 5 years 12/4/1997 – 5/31/2003
Amount: \$2,782,847
Source of support: NIH/DHHS
Investigators: C Fabian (PI), Tawfik, MD, PhD (Co-investigator), et al.
Dr Tawfik's %effort 3%

Characterization and prevention of intestinal ischemic injury

Project period: 2 years 6/1/2000 – 5/31/2003
Amount: \$238,972
Source of support: March of Dimes
Investigators: R Sonnino, MD (PI), Tawfik, MD, PhD (Co-investigator)
Dr Tawfik's % effort 10%

Phase IB Study of Biomarker Modulation by Celecoxib in Newly-Diagnosed Breast Cancer

Project period: 2 years 7/1/02-6/30/04
Amount: \$1,749,730
Source of support: Pharmacia & Upjohn Company
Investigators: CJ Fabian, MD (PI), Tawfik, MD, PhD (Co-investigator), et al.
Dr Tawfik's % effort: 12.5%

Mineralization studies related to atherosclerosis

Project period: 3 years 4/1/2002 – 3/31/2005
Amount: \$787,500
Source of support: NIH/DHHS
Investigators: Howard Hsu, PhD (PI), Tawfik, MD, PhD (Co-investigator)
Dr Tawfik's % effort: 10%

Liposomal doxorubicin in combination with the biological response modifiers Imm-Kine and C-Statin for patients with advanced recurrent ovarian cancer – A pilot study.

Project period: 2 years 4/2/2003 – 5/17/2005
Amount: \$307,238
Source of support: Cancer Treat Res Foudation
Investigators: Jean Drisko, MD (PI), Tawfik, MD, PhD (C0-investigator)

b) Current grants:

Mast cell-induced inflammation in vascular disease.

Project period: 5 years 02/01/2006 - 01/31/2011
Amount: \$1,250,000.00
Source of support: R01 HL07010
Investigators: Kottarappat N. Dileepan, PhD (PI), Tawfik, MD, PhD (Co-investigator)
Dr Tawfik's % effort: 2%

The objectives of this project are to elucidate the mechanisms by which mast cell-derived proteases and histamine modulate innate immune responses to microbial pathogens and enhance progression of atherosclerosis.

Training program in environmental toxicology.

Project period: 5 years 07/01/2006 – 06/30/2011
Amount: \$268,188
Source of support: NIH/NIEHS 2T32 ES07079-26A2
Investigators: C Klaussen, PhD (PI), Tawfik, MD, PhD (Co-investigator)
Role: Mentor

This is a grant for the training of graduate and post-graduate students in toxicology.

Vitamin D as Therapy for Human Osteosarcoma

Project period: 1 years 03/01/2008 – 02/28/2009
Amount: \$20,000.00
Source of support: Departmental internal funds
Investigators: Tawfik, MD, PhD
Role: PI

c) Pending grant proposals

Promotion of Estrogen-Induced Breast Tumors by Alcohol

Project period 5 years
Amount 1,000,000
Source of support NIH/DHHS
Investigators: J Li, PhD (PI), Tawfik, MD, PhD (Co-investigator), et al.
Dr Tawfik's % effort 5% (consultant)

The major goal of this project is to study the relationship of alcohol and breast cancer

My role includes histopathologic evaluation of the different neoplasms and premalignant lesions induced by alcohol administration and immunohistochemical and morphometric analysis of the different lesions.

Measurement of various tumor markers in radical prostatectomy specimens following Proscar for treatment

Project period	2 years
Source of support:	Merck
Investigators: P Langenstroer, MD (PI), Tawfik, MD, PhD (Co-investigator), et al.	
Dr Tawfik' s% effort	5%

The objective of this study is to prospectively evaluate the effects of finasteride on apoptotic pathways in patients with localized prostate cancer.

In this study, my laboratory will be in charge of evaluating all the prostate samples collected in the study, develop and evaluate immunohistochemical studies for the different biomarkers affected by the medication.

J. Clinical Activities:

Since my appointment as director of the surgical pathology division in our department my goal was and still remains to build this division into one of the best in the country. I have truly believed that our team could accomplish this goal. Today, I am proud to say that the division of surgical pathology at KU has tremendously improved and is respected by clinicians and hospital administrators.

As director of surgical pathology, my primary responsibility is to provide clinical expertise in the areas of surgical pathology, hematopathology, and cytopathology (including fine needle aspiration) for at least 8-9 months of the year. My particular arena is in **urogenital pathology, gynecologic, reproductive and breast pathology and Tumor Biology**. Surgical pathologists are on call 24 hours a day and have to be ready to provide the best possible medical service to our patients and give our fellow clinicians appropriate and reliable consultation. When on service, it is not uncommon to spend 12-13 hours of work/day. Although I examine all surgical and cytologic cases that come my way when on service, I also have several areas of interest. These include pulmonary, gynecologic and breast pathology. I am the designated liaison pathologist with the obstetrics and gynecology and pulmonary clinicians. That involves daily contact with the clinicians to discuss surgical and cytologic specimens for their patients including my own cases as well as in-house and outside-referred cases. When I am on surgical pathology service my daily work includes intraoperative consultations, gross and microscopic evaluation of the specimens, immunohistochemical and electron microscopic analysis and reporting the diagnostic findings. On average I review 40-50 cases/day. This is in addition, to in-house and outside consultations (5-10 cases/day). On the cytology rotation, I review 40-50 cases/day. In addition, I perform fine needle aspiration on in and outpatients that come to the various clinics in the hospital.

Clinical Goals and Accomplishments:

1. I joined the **International Urologic Pathology Society** and was appointed to the **editorial board of the J of Urologic Pathology (from 1999-present)**.

2. Numerous publications in the field of urologic pathology with one of my publications designated as the **CME article of the month in Urology Journal in 1996.**
3. I developed a strong collaborative research relationship with the University of Alabama at Birmingham. These efforts were awarded an **NCI grant** and continue today in on-going collaborative efforts
4. KUMC has been approved to become a member of the **GYNECOLOGIC ONCOLOGY GROUP (GOG).** My role in this effort is to provide proper diagnosis for patients to be enrolled in clinical trials.
5. I similarly provide expertise in the field of Pediatric Pathology that enabled our school to become a member of the **CHILDREN'S ONCOLOGY GROUP (COG).**
6. In the arena of **gynecologic and Breast Pathology,** I regularly receive 5-10 cases per week from outside universities on which my consultation is requested.
7. In the arena of **tumor biology and biomarkers** we have established a state of the art immunohistochemistry and nuclear morphometry laboratory. These services have been recognized by the hospital in their annual report, the University, as well as locally and nationally. Our services has been featured in the front page of the KANSAN newspaper and televised on **KCTV 5, Health Watch** program with national broadcasting, providing new ways of improving the diagnostic accuracy by the pathologists for breast and ovarian cancer.
8. Our expertise in tumor biology were instrumental for the success of Dr Fabian and her group in getting awarded several NCI grants to study breast cancer.
9. Because of my successful relationship with the OB/GYN department, I was given a clinical appointment in OB/GYN. I conduct weekly working conferences with the clinicians in those areas. I am also in charge of the pathology part of the weekly pulmonary conference and rotate with the other surgical pathologists in the multidisciplinary breast tumor conference. I am also the designated pathologist for the lung transplantation program at KU that will be starting soon, as well as the backup pathologist for the liver transplant program.

As a director of surgical pathology I have a substantial administrative responsibility with a substantial contribution to several committees and working groups of the school and University. Examples of such activities include:

Internal Efforts:

- | | |
|------------------|--|
| 1997-1999 | Acting-Director of Surgical Pathology |
| 1999-present | Director of Surgical Pathology |
| 1995-present | Director of Immunohistochemistry Laboratory |
| 1996-present | Director of Image Analysis and Nuclear Morphometry Laboratory |
| 1998-2002 | Co-Chair of the Surgical Pathology task Force Committee |
| 1998-2002 | Chair of the institutional Surgical Case Review Committee |
| 1999-2003 | Faculty Council member |
| 2000-2002 | KUPI Board of Directors member |
| 2000-2001 | Space Committee for Lab renovation member |

1999-2002 Departmental Committee and Task Forces including; **Executive Committee, Research and Graduate Committee, Financial Committee and Residency Review Committee, Section Directors Committee.**

1998-present Vice-president, University Pathologists Association

2002-2006 **Executive Committee of the Medical Staff**

2002-2006 Elected medical staff officer

2001-present **School of Medicine Research Committee (Chair-2003-2004)**

2003-present Director of the tumor repository of the Kansas Cancer Institute

2003-present Kansas Univ. Physicians, Inc Practice Operations Committee member

2004-present Director of Anatomic pathology

2004-present Member of the departmental promotion and tenure committee

2006-present Kansas Univ. Physicians, Inc Pension and Benefits Committee member

2006 Credentials committee

2007-present General Clinical Research Center (GCRC) Advisory Committee member

External Efforts:

As mentioned before, I am a member and active participant of the following organizations:

- Gynecologic Oncology Group
- Children's Oncology Group
- Kansas City Society of Pathologists, (Past President, CME course director)
- Kansas Chapter, Arab American Medical Association, (Past President, CME course director)
- Anatomic Directors and Surgical Pathology Directors Association

I was also instrumental in establishing and setting up several business opportunities for our department.

1. We have now surg path, cytology and Fine needle aspiration services, including a frozen sectioning facility at one of our satellite clinics in town (K U Med West).
2. Surgical pathology services for a Kansas City private practice group. These services are totally performed at our University hospital with computer connection to the pathology system in private practice. This has helped increase consultation services and the performance of more esoteric tests not performed in a smaller facility
3. In an effort to improve our immunohistochemistry services, I worked on developing a state of the art immunohistochemistry laboratory that is fully automated. This laboratory is considered the reference lab for many of the pathology groups in town. These efforts were improved by the recent addition of the ChromaVision Automated Imaging System to further standardize and improve our diagnostic accuracy. These changes have significantly increased our revenues
4. Image analysis services and morphometric studies for a variety of benign and malignant tumors, including breast, gynecologic, gastrointestinal, lung, brain and urologic tumors. These studies have become of utmost importance for not only the diagnosis, but for decision making as far as treatment and prognosis of such tumors.

K. Teaching Activities:

My goal as an academician has always been to encourage young clinicians and scientists to publish their results. My teaching philosophy has always been to involve students, residents and technician in all of my academic endeavors. In all of my publications, residents, students and technicians were included as key partners. My belief is every resident/student should be offered the opportunity to get involved in a research project. I do believe that such experience would have a great impact on their career.

In the teaching arena, I have participated in developing courses and curricular material for the residents and students, organization, supervision and evaluation of regional and international activities, and writing textbooks.

CME Activities:

Because of my interest and academic background I was elected by members of 2 regional organization (Kansas City Society of Pathologists and the Kansas Chapter of the Arab American Medical Association) to be the CME course director. My role includes organization, implementation and evaluation of the educational activities, supervision of the educational programs. As a course director my role included CME approval from the national office and implementation of the guidelines for each organization.

Pathology Residency Training Program:

My teaching responsibilities are subdivided as follows:

1) Didactic Lectures:

Over the past five years I have regularly lectured in the following areas: Breast pathology, OB/GYN pathology (vulvar and vaginal diseases, uterine pathology and ovarian pathology) and pulmonary pathology including infectious diseases, interstitial lung diseases and lung tumors. Additional didactic lectures include renal pathology, cardiac pathology, transplantation pathology, salivary gland pathology, dermatopathology, thyroid pathology, and spleen pathology. Those lectures were directed to Pathology, Obstetrics and Gynecology, Ear, Nose and Throat, Radiation Oncology, Urology, and Pulmonary Medicine residents and fellows.

Recently I have expanded my role in teaching by organizing a core anatomic pathology curriculum for our pathology residents and I have also increased by teaching residents and fellows in other departments such as Ear, Nose and Throat, Radiation Oncology, Urology and Cardiology

I also direct a didactic course in cytopathology for the pathology residents with the assistance of Marilee Means, PhD cytotechnologist and supervisor of the cytology laboratory. This course is offered over a 2-year period. The main emphasis during the first year is on gynecologic cytology. In the second year, we cover fine needle aspiration cytology as well pulmonary, thyroid, salivary gland, gastroenterology, genitourinary, soft tissue tumors, and body fluid cytology.

2) Daily Supervision of Residents:

This activity includes very close supervision and observation of rotating residents in surgical pathology, cytology and hematopathology. I am directly involved with the residents throughout the process of evaluating the surgical specimens (from the moment the specimens arrive in the laboratory until the final report is issued). This process includes specimen gross evaluation, sectioning, staining, photographing, microscopic evaluation and reporting. In addition, I am a strong advocate for educating the residents in how to take an active part in patient care and develop strong communication skills with clinicians and lab personnel. I usually ask the residents to evaluate the clinical history of patients carefully, seek relevant medical, radiologic and other laboratory information.

3) Conferences at which I present weekly or monthly:

I play a major part in organizing and coordinating a number of regularly held teachings and clinical conferences in our department as well as others:

Surgical Pathology Conference (daily)

Tumor Conference (weekly)

Obstetrics and Gynecology pathology Conference (monthly)

Multidisciplinary Breast Tumor Conference (weekly)

Anatomic Pathology Conference (biweekly)

Cytopathology Conference (monthly)

Pulmonary Conference (monthly)

Urology conference (monthly)

Head and Neck Pathology (weekly)

Sarcoma and Bone tumors multidisciplinary conference (monthly)

Cardiac pathology (3 times/year)

4) Miscellaneous Educational Activities:

I am actively involved in assisting our Pathology and Obstetrics and Gynecology, Ear, Nose and Throat, Surgery, Radiation Oncology, Urology and Cardiology residents in Surgical Pathology and Cytology rotations in manuscript preparation and in oral and poster presentations for regional and national meetings

Number of residents:

Currently the department has 14 residents including 2 surgical pathology/ cytology fellows. All of them rotate for at least 6 months of the year in surgical pathology, cytology and hematology. In the last 2 years, I was responsible for mentoring 6 OB/GYN residents (3/year). Each of those residents has spent one month in surgical pathology and cytology under my supervision.

Time spent:

I spend at least 3 hours/day teaching the residents

Medical Student's Teaching:

Course Title:

Pathology 850 and 851

For the last several years (1995-2005) I have been in charge of teaching Obstetrics and Gynecology and Breast Pathology sections of the second year medical students pathology course. Those 2 sections are divided into 5 didactic 1 hour lectures.

In the academic years of 1992 to 1994, I was in charge of teaching 2 lectures/year; interstitial lung diseases and diseases of pregnancy

I am also involved in teaching the weekly small group (preceptorial) sessions to second year medical students. Those are 2-hour sessions in which I discuss the important clinical and histopathologic features of the topic of the week. This amounts to 52 contact hours/year.

For the last 10 years I assisted 12 medical students in the Pathology Honor Society in their case presentations. With 3 of these students, I submitted 4 manuscripts for publication; all were accepted.

Cytotechnology and Medical records Students:

I also assisted in the education of the students in our cytotechnology training program. and gave the Pathology of the Immune System lecture to the Medical records students for 4 years.

Teaching Activities:

Courses:

Year	Title of Course	No.of Students	Length of Course	Cat. Of Students
1995-present	Pathology Special Electives	1-4	2-4 hr/wk 24 wks	Medical students
2000-present	Problem Based Learning (PBL)	12	3 hr/biweekly (including prep) 16wks	Medical Students
1992-2000	Small groups	20	3 hr/biweekly	Medical students
1998-00	Pathology Case Analysis	22	3 hr/wk (including prep) 32 wks	medical Students
1992-present	Lectures Pathology PAON 850/851	175	15 hrs (including prep)	Medical Students

Clinical Teaching and Interdepartmental Conference

Year	Title of Course	No.of Students	Length of Course	Cat. Of Students
1994-2000	Multidisciplinary Breast Tumor Conference	20	2-6 hr/wk Including Prep with Fellow, case Reviews	Residents, Fellows, Nurses, & Faculty physicians
1997-2000	Cytology Microscope Conference	8	1 hr 12 wks	Cytotechnologists, Cytotechnology Students, and Residents
1995-present	Multidisciplinary Sarcoma Conference	20	2-6 hr/wk Including Prep with Res and Fellow, Case reviews	Residents, Fellows, & Faculty physicians
1995-2000	Multidisciplinary Tumor Board	40	2-6 hr/wk Including Prep with Fellow, case	Residents, Fellows, Nurses, & Faculty physicians
1994-present	Multidisciplinary Obstetrics and Gynecology Conference	40	2-6 hr/wk Including Prep time	Residents, Fellows, Nurses, & Faculty physicians
2001-2002	Cardiac pathology Conference	25	6 hr/month Including Prep time	residents, Fellows & faculty physicians
1995-present	Pulmonary pathology Conference	20	6 hr/month Including Prep time	residents, Fellows & faculty physicians
1998-present	Urologic pathology Conference	15	6 hr/month Including Prep time	residents, Fellows & faculty physicians
1995-1997	Pediatric Oncology Conference	10-15	1 hr/wk 12 wks	Residents and Fellows

Intradepartmental Conferences, Grand Rounds, Journal Club:

Didactic lectures to residents, students and fellows in pathology

- Pathology of the ovary
- Pathology of the endometrium
- Pathology of the myometrium
- Pathology of the cervix
- Pathology of the vulva and vagina
- Placental pathology
- Interstitial lung diseases
- Neoplastic diseases of the lung
- Breast pathology
- Prostate pathology
- Urinary bladder pathology
- Renal tumors pathology
- Splenic pathology
- Soft tissues and bone pathology
- Cardiac transplant pathology
- Cardiomyopathies
- Cardiac tumors pathology
- Vasculitides

Didactic and microscope sessions with residents, students and fellows in;

- Radiation oncology: Breast pathology
- Pulmonary Medicine: Lung tumors, cytopathology and interstitial lung diseases
- Obstetrics and Gynecology: Ovary, uterus, cervix, vagina, vulva, and placental pathology
- Ear, Nose and Throat: Thyroid, salivary gland, skin, lymph node, soft tissue and pharynx and larynx pathology

I. Masters and Ph.D. theses directed and postdoctoral fellows supervised:

<u>Name</u>	<u>Program/Year</u>	<u>Last known status</u>
Emma Khan, MD	Cytopathology Fellow 2009-2010	Current fellow
Steven LaRue, MD	Cytopathology Fellow 2009-2010	Current fellow
Xiaoying Liu, MD	Cytopathology Fellow 2008-2009	Academic pathologist
Maura O’Neil, MD	Cytopathology Fellow 2008-2009	Academic pathologist
Katie Dennis, MD	Cytopathology Fellow 2008-2009	Academic pathologist
Soheila Hamidpoour, MD	Cytopathology Fellow 2007-2008	Private practice
Xiao Wang, MD	Cytopathology Fellow 2007-2008	Private practice
Jaiyeola Thomas, MD	Cytopathology Fellow 2007-2008	Academic pathologist

Xin Gao, MD	Cytopathology Fellow	2006-2007	Academic pathologist
Bradley Carmichael, MD	Cytopathology Fellow	2006-2007	Private practice
Pablo Hernandez-Rios, MD	Cytopathology Fellow	2005-2006	Private Practice
Maria Romanas, MD, PhD	Cytopathology Fellow	2005-2006	Academic Pathologist
Barbara Sheideler, MD	Cytopathology fellow	2004-2005	Private practice
Asraa Namiq, MD	Cytopathology fellow	2003-2004	Academic pathologist
John Donahue, MD	Cytopathology Fellow	2002-2003	Private practice
Fang Fan, MD, PhD	Cytopathology Fellow,	2001-2002	Academic pathologist KUMC, 2002
Yafei Ren, MD, PhD	Cytopathology Fellow,	2000-2001	(Private Practice)
Elizabeth McKinley, MD	Cytopathology Fellow,	1999-2000 KUMC, 2000-2002;	(Academic Pathologist, Private Practice)
Paul Munyer, MD, PhD	Cytopathology Fellow,	1999-2000	(Private Practice)
Patricia Webb, MD	Cytopathology Fellow,	1998-1999	(Private Practice)
Sahar Samaha, MD	Cytopathology Fellow,	1998-1999	(Private Practice)
Kenneth Iczkowski, MD	Surg Path Fellow,	1997-1998	Academic pathologist
Shaheen Ahmed, MD	Surg Path Fellow,	1996-1997	(Private Practice)
Elizabeth Friedman, MD	Surg Path Fellow,	1995-1996	(Private Practice)
Janet Woodroof, MD	Surg Path Fellow,	1994-1995	(Acad Path, then Private)

Member of PhD and Master's committees for the following graduate students:

Wenjia Wang	PhD	2006-present	PhD student
Adrienne Hontz	PhD	2005-2008	PhD student
John Weroha	PhD	2003-2006	PhD student
Yue Xue	PhD	2000-2004	PhD student
Ramah Sharma	PhD	2001-2004	PhD student
Ryan Gill	MD, PhD	2001-2003	PhD student
Joseph Sipe	MS	2001-2004	MS student

M. Administration:

2001-present	School of Medicine Research Committee
2000-2001	President elect, Arab American Medical Association (AAMA), Kansas Chapter
2001-2002	President, Kansas City Society of Pathologists
2001	CME director of Kansas City Society of Pathologists
2002-2003	Past President, Kansas City Society of Pathologists
2000-2002	KUPI Board of Directors member
1999-2004	Faculty Council member
1998-2003	Hospital Surgical Case Review Committee, Chair
1998-present	CME director of AAMA, Kansas Chapter
1997	Clinical PPAC Committee
1991-1996	Reproductive Biology Resource Committee, College of American Pathologists
1999-present	Director of Surgical Pathology
1995-present	Director of Immunohistochemistry laboratory

1996-present	Director of Image Analysis and Nuclear Morphometry laboratory
1999-present	Surgical Pathology Task Force Committee, Co-Chair
1998-1999	Acting Director of Surgical pathology
1998-present	Vice President of the University Pathologists Association
1992-present	Residency Review Committee
1992-present	Departmental Graduate and Research Committee
1996-current	Departmental Finance Committee
1992-1996	Residency Program Director
1997-1993	Co-director of the KUMC Tumor Repository
1993-present	Director of the KUMC Tumor Repository
2002-2006	KU MED Executive Committee of Medical Staff
2002-2006	KU MED medical staff elected officer
2004-present	Director of Anatomic and Surgical Pathology
2006-present	Vice Chairman for Education and Outreach
2007-2008	Diagnostic Immunology Resource Committee, College of American Pathologists

N. Physical Facilities Available:

1.	Office	Room and Building	1615 Bell Hospital	40 Sq. Ft.
----	--------	-------------------	--------------------	------------

O. Full Length Papers in Scientific Journals:

1. Manuscripts already published:

1. Rachel JM, Sinor LT, **Tawfik O**, Summers TC, Beck ML, Bayer WL and Plapp FV. A solid-phase red cell adherence test for platelet crossmatching. *Med Lab Sci* 42:194, 1985
2. **Tawfik O**, Hunt JS and Wood GW. Partial characterization of uterine cells responsible for suppression of maternal anti-paternal immune response. *J Reprod Immunol* 9:213, 1986
3. Wood GW, **Tawfik O** and Hunt JS. Regulation of maternal anti-paternal immune response in vitro by uterine macrophages. *Trophoblast Research* 2:161, 1987
4. **Tawfik O**, Hunt JS and Wood GW. Implication of prostaglandin E₂ in soluble factor mediated immune suppression by murine decidual cells. *Am J Reprod Immunol Microbiol* 12:111, 1986
5. **Tawfik O**, Sagrillo C*, Johnson DC and Dey SK. Decidualization in the rat: role of leukotrienes and prostaglandins. *Prostaglandins, Leukotrienes and Medicine* 29:221, 1987
6. **Tawfik O**, Huet YM*, Malathy PV*, Johnson DC and Dey SK. Release of prostaglandins and leukotrienes from the rat uterus is an early estrogenic response. *Prostaglandins* 34:805, 1987
7. **Tawfik O**, Dey SK. Further evidence for role of leukotrienes as mediators of decidualization in the rat. *Prostaglandins* 35:379, 1988

8. Chakraborty C, **Tawfik O** and Dey SK. Epidermal growth factor binding in rat uterus during the peri-implantation period. *Biochem Biophys Res Comm* 153:564, 1988
9. **Tawfik O**, Papasian CJ, Dixon AY and Potter LM. *Saccharomyces cerevisiae* pneumonia in a patient with acquired immune deficiency syndrome. *J Clin Microbiol* 27:1689, 1989
10. **Tawfik O**, McGregor D. Lipohyperplasia of ileocecal valve. *Am J Gastroenterol* 87:82, 1992
11. **Tawfik O**, Moral LA, Lee KR and Richardson WP. Multicentric bilateral renal cell carcinomas and vascular leiomyoma in a child. *Ped Path* 13:289, 1993
12. Seoud M*, **Tawfik O**, Hunter V: Case report. Peritoneal papillary serous carcinoma in a woman with a history of in Utero DES exposure. *Gynecol Oncol* 50:371, 1993
13. **Tawfik O** and Fishback J. Disseminated cryptococcosis with hypothyroidism in an AIDS patient. *Kansas Medicine* 94:273, 1993
14. **Tawfik O**, Mowry M*, Huntrakoon M. Coincidental metastatic intestinal neuroendocrine carcinoma and esophageal adenocarcinoma. *Kansas Medicine* 94:327, 1993
15. Members of the College of American Pathologists/American Fertility Society Reproductive Biology Resource Committee. Culture medium for in vitro embryo culture (IVF) survey. 1993 College of American Pathologists Surveys. Set RB-2A
16. Members of the CAP/AFS Reproductive Biology Resource Committee. Culture media for in vitro embryo culture (IVF) survey. 1993 College of American Pathologists Surveys. Set RB-2B
17. **Tawfik O**, Huntrakoon M, Collins J**, Oweity T*, Seoud M, Weed J. Leiomyosarcoma of the vulva. Report of a case. *Gynecol Oncology* 54:242, 1994
18. Craven TG*, Toby EB, **Tawfik O**. The effect of delayed microsurgical arterial anastomosis on arterial patency. *J Reconstruct Microsurg* 11:1, 1995
19. Lawson *L, VanLerberg N**, **Tawfik O**. Pulmonary metastasis from a benign giant cell tumor of the hand. Report of a case diagnosed by fine needle aspiration cytology. *Diagn Cytopath* 15:157, 1996
20. **Tawfik O**, Huntrakoon M, Noble M, Freeman F. Adenocarcinoma of the Anterior Urethra in the Male. A Case report and Review of the Literature. *Kansas Medicine* 97:26, 1996
21. **Tawfik O**, Austenfeld M, Persons D. Muticentric renal angiomyolipoma with pulmonary lymphangioliomyomatosis. Report of a case with histological, immunohistochemical and DNA content analysis. *Urology* 48:476, 1996
22. Ault KA, **Tawfik O**, Smith-King M*, Gunter J*, Terranova P. Tumor necrosis factor-alpha response to infection with *Chlamydia trachomatis* in human fallopian tube organ culture. *Am J Obstet Gynecol* 175:1242, 1996

23. **Tawfik O**, Venuti S*, Brown S, Collins J**. Immunohistochemical characterization of leukocytic subpopulations in chronic endometritis. *Infect Dis Obstet Gynecol* 4:287, 1997
24. Cooper LT, Berry GJ, Shabetal R, Multicenter Giant Cell Myocarditis Study Group Investigators (**Tawfik O**). Idiopathic giant cell myocarditis. Natural history and treatment. *New Engl J Med* 336:1860, 1997
25. Whitaker C*, **Tawfik O**, Weed JC Jr. Serous cystadenofibroma arising in an ectopic ovary. A case report. *Kansas Medicine* 98:24, 1997
26. **Tawfik O**, Balarezo F*, Weed JC. Splenosis; a report of ovarian stromal involvement. *Kansas Medicine* 98:14, 1997
27. **Tawfik O**, Prather J, Bhatia P, Woodroof J, Gunter J, Webb P. Vernix caseosa peritonitis. A rare complication of cesarean section. *J Reprod Med* 43:547, 1998
28. **Tawfik O**, Newell B*. A rare case of segmental absence of intestinal musculature in an adult. *Digest Dis Science* 43:397, 1998
29. Samaha S*, **Tawfik O**, Horvat R, Bhatia P. Lymphoepithelioma-like carcinoma of the colon. Report of a case with clinical, pathologic, immunohistochemical and molecular biology studies for Epstein-barr virus. *Dis Colon Rectum* 41:925, 1998
30. Kamel S, Zeiger S, Zalles C, **Tawfik O**, Kimler B, Fabian C. p53 immunopositivity and gene mutation in a group of women at high risk for breast cancer. *Breast J* 4:396, 1998
31. **Tawfik O**, Tsue T, Pantazis C, Nuckols D, Younes S*, Webb P*. Salivary gland neoplasms with basaloid features. Report of two cases diagnosed by fine-needle aspiration cytology. *Diagn Cyto pathology* 21: 46, 1999
32. Wang Y-Y, **Tawfik O**, Wood GW. Endotoxin-induced abortion in mice is mediated by activated fetal macrophages. *J Leuk Biol* 63: 40, 1998
33. Fan F*, **Tawfik O**, Bhatia P, Lee KR. Hepatic undifferentiated (embryonal) sarcoma. A case report with fine needle aspiration cytology and histology. *Ped Pathol Mol Med* 18: 221, 1999
34. Raghavan R, Alley S, **Tawfik O**, Webb P, Forster J, Uhl M. Splenic peliosis. A rare complication following liver transplantation. *Dig Dis Science* 44: 1128, 1999
35. Lu D*, **Tawfik O**, Pantazis C, Hobart W, Chapman J. Altered expression of CD44 and variant isoforms in human adenocarcinoma of the endocervix during progression. *Gynecol Oncology* 75:84, 1999
36. **Tawfik O**, Casparian MJ, Garrigues N, Smith S, Kastenbaum T, Chamberlin F, Khan QS. Neuroendocrine differentiation of a metastatic basal cell carcinoma in a patient with basal cell nevus syndrome. *J Cut Pathol* 26: 306, 1999

37. Hsu HH, **Tawfik O**, Sun F. Effects of lectins on calcification by vesicles isolated from aortas of cholesterol-fed rabbits. *Biochem Biophys Acta* 1464: 262, 2000
38. Roby KF, Taylor CC, Cheng Y, Pace JL. **Tawfik O**, Persons D, Smith P, Terranova P. Development of asyngeneic mouse model for events related to ovarian cancer. *Oncogenesis* 21:585, 2000
39. Moseley AC*, Lindsley HB, Skikne BS, **Tawfik O**. Reversible methotrexate-associated lymphoproliferative disease evolving into Hodgkin's disease. *J Rheumatology* 27:3, 2000
40. Hsu H, Camacho NP, Sun F, **Tawfik O**, Aono H. Isolation of calcifiable vesicles from aortas of rabbits fed with high cholesterol diets. *Atherosclerosis* 153; 337, 2000
41. Ren Y*, Munyer P*, Kepes JJ, Cansler M**, Collins J**, Gayed B*, **Tawfik O**. A comparison of Cyclin A and MIB-1 expression in astrocytic tumors utilizing image-based cell analysis system (CAS-200). *Appl Immunohisto Mol Morphol* 9; 14, 2001
42. Krishnan L, Jewell WR, **Tawfik O**, Krishnan EC. Ductal carcinoma in situ of the breast treated with breast-conserving surgery and radiotherapy. *The Breast J* 7: 91, 2000
43. Fan F*, Lee KR, Thrasher B, **Tawfik O**. Localized retroperitoneal fibrosis with perirenal involvement: A diagnostic challenge. *J Urol Pathol* 12, 117, 2000
44. Owiety T*, Persons D, **Tawfik O**. Carcinosarcoma of the prostatic urethra. Report of a case following radiation treatment for prostatic adenocarcinoma. *J Urol Pathol* 12: 199, 2000
45. Nothnick W, Fan F*, Iczkowski KA*, Ashwell R*, Thomas P, **Tawfik O**. CD44s expression is reduced in endometriotic lesions compared to eutopic endometrium in women with endometriosis. *Int J GYN Pathol* 20: 140, 2001
46. Gatalica Z, Finkelstein S, Lucio E, **Tawfik O**, Palazzo J, Hightower B, Eyzaguirre E. p53 protein expression and gene mutation in phyllodes tumors of the breast. *Pathol Res Pract* 197: 183, 2001
47. Asadi M*, Bennett C, **Tawfik O**. Colonic Lipoma: An usual presentation with intussusception and obstruction. *Practical Gastroenterology* 25: 41, 2001
48. Li JJ, Weroha SJ*, **Tawfik O**, Cansler M**, Hou X, Li SA. Estrogen and progesterone receptors in renomedullary interstitial cells during Syrian hamster estrogen-induced tumorigenesis: Evidence for receptor-mediated oncogenesis. *Endocrinology* 142:4006, 2001
49. Ren Y*, Raitz ER, Lee KR, Pingelton SK, **Tawfik O**. Pulmonary small lymphocytic lymphoma (MALT-Type) associated with pulmonary hyalinizing granuloma. *Chest* 120: 1027, 2001
50. Templeton KJ, Langford S*, **Tawfik O**. Extramedullary plasmacytoma of the hand: A case report. *J Hand Surg* 26: 781, 2001

51. Azma A*, **Tawfik O**, Casparian JM. Apocrine Poroma of the Breast. *Breast J* 7: 195, 2001
52. Kusumoto M, Umeda S, Ikubo A, Aoki Y, **Tawfik O**, Oben R, Williamson S, Jewell W, Suzuki T. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with Human GM-CSF gene. *Cancer Immunol Immunother* 50: 373, 2001
53. Pantazis C, Templeton K, **Tawfik O**, Braylan R. Langerhans cell granulomatosis manifested as pigmented villonodular synovitis. *J Southern Ortho Assoc* 10:230, 2001
54. Li, JJ, Papa D*, Davis M**, Weroha SJ*, Aldaz CM, El-Boyoumy K, Ballenger J, **Tawfik O**. Li SA. Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: Comparison to invasive human ductal breast cancer. *Mol Carcinogenesis* 33: 56, 2002
55. Tan J, Raja S, Davis MK**, **Tawfik O**, Dey SK, Das SK. Evidence for coordinated interaction of cyclin D3 with p21 and cdk6 in directing the development of uterine stromal cell decidualization and polyploidy during implantation. *Mechanisms of Development* 111: 99, 2002.
56. Ferrer J, Namiq A*, Carda C, **Tawfik O**, Llombart-Bosch A. Diffuse-type of giant cell tumor of tendon sheath: An ultrastructural study of two cases. *Ultrastructural Pathol* 2002, 26:15
57. Asadi M*, Forster J, **Tawfik O**. Hemangiopericytoma of the liver: report of a case and review of the literature. *Pract Gastroenterol* 2002, 25: 68
58. Sonnino RE, Cross RE**, **Tawfik O**. Mediators of ischemia in preserved intestinal grafts. *Transplant Proc* 2002, 34:975
59. Templeton KJ, Ren Y*, **Tawfik O**. Soft tissue mass in a 9-year-old boy. *Clin Orthop* 2002, 399:247-52, 272-4
60. Johnston TP, Coker JW, Paigen BJ, **Tawfik O**. Sex does not seem to influence the formation of aortic lesions in the P-407-induced mouse model of hyperlipidemia and atherosclerosis. *J Cardiovasc Pharmacol* 2002, 39:404
61. Ellis RJ*, Fabian C, Kimler B, **Tawfik O**, Mayo M, Decelis C, Jewell W, Connor C, Modrell C, Praeger M, McGinness M, Mehta R, Fruehauf J. Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens. *Breast Cancer Research and Treatment* 2002, 71:95
62. Hsu HHT, **Tawfik O**, Sun F. Mechanisms of calcification by vesicles isolated from atherosclerotic rabbit aortas. *Biochem Biophys Acta*, 2002, 1563:18
63. Hsu HH, Camacho NC, **Tawfik O**, Sun F. Induction of calcification in rabbits aortas by high cholesterol diets: roles of calcifiable vesicles in dystrophic calcification. *Atherosclerosis* 2002, 161:85

64. Connor CS, **Tawfik O**, Joyce AJ*, Davis MK**, Mayo MS, Jewell WR. A comparison of prognostic markers obtained on Image-Guided breast biopsies and final surgical specimens. *Am J Surg* 2002, 184:322
65. Iczkowski KA, Pantazis CG, McGregor D Wu Y, **Tawfik O**. Telomerase reverse transcriptase subunit immunoreactivity: A marker for high-grade prostate cancer. *Cancer* 2002, 95:2487
66. Li SA, Weroha SJ*, **Tawfik O**, Li JJ. Prevention of solely estrogen-induced mammary tumors in female ACI rats by Tamoxifen: Evidence for estrogen receptor mediation. *J Endocrinol* 2002, 175: 297
67. Yin C*, Chapman J, **Tawfik O**. Invasive mucinous adenocarcinoma of ectopic breast tissue in the vulva: A case report. *The Breast J* 2003, 9:113
68. Banerjee S, Saxena N, Sengupta K, **Tawfik O**, Mayo MS, Banerjee SK. WISP-2 gene in human breast cancer: Estrogen and progesterone inducible expression and regulation of tumor cell proliferation. *Neoplasia* 2003, 5:63
69. Devaiah AK, Larsen C*, **Tawfik O**, O'Boynick P, Hoover LA. Esthesioneuroblastoma: Endoscopic nasal and anterior craniotomy resection. *Laryngoscope* 2003, 113:2086.
70. Gavallos G*, **Tawfik O**, Herrell D, Langenstroer P. Renal-Ovarian axis: A case report and review. *Urology*. 2003, 62:749.
71. Tomita T, Ren Y*, Davis M**, **Tawfik O**. Phylloides tumor of borderline malignancy: A 7-year follow-up with immunohistochemical study. *Breast J* 2003 9:333.
72. Weed J, Adam Graff*, Shoup B*, **Tawfik O**. Small cell undifferentiated (neuroendocrine) carcinoma of the cervix. A clinical study of 15 patients and review of the literature. *J Am Coll Surg*. 2003 ;197:44.
73. Schloerb PR, Wood JG, Casillan AJ, **Tawfik O**, Udobi K. Bowel necrosis due to water in jejunal feeding. *J Parenteral & Enteral Nutrition* 2004, 28:27.
74. Hsu HHT, **Tawfik O**. Sun, F. Mechanisms of dystrophic calcification in rabbit aortas: Temporal and spatial distributions of calcifying vesicles and calcification-related structural proteins. *Cardiovascular Path* 2004, 13: 3-10.
75. Tan Y, Li M, Cox S, Davis MK**, **Tawfik O**, Paria BC, Das SK. HB-EGF directs stromal cell polyploidy and decidualization via cyclin D3 during implantation. *Dev Biol*. 2004, 265:181.
76. He XC, Zhang J, Tong WG, **Tawfik O**, Ross J, Scoville DH, Tian Q, Zeng X, He X, Wiedemann LM, Mishina Y, Li L. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. *Nat Genet*. 2004 36:1038.

77. Fabian CJ, Kimler BF, Anderson J**, **Tawfik O**, Mayo MS, et al. Breast cancer chemoprevention Phase I evaluation of biomarker modulation by Arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res. 2004; 10:5403.
78. Gunter J, Brewer A, **Tawfik O**. Botulinum toxin A for vulvodynia: A case report. Journal of Pain 2004; 5:238.
79. Fan F, Pietrow P, Wilson LA, Romanas M*, **Tawfik O**. Adrenal pseudocyst: A unique case with adrenal renal fusion, mimicking a cystic renal mass. Ann Diagn Pathol 2004, Ann Diagn Pathol. 2004; 8:87.
80. Imkie M*, Myers SA, Li Y, Fan F, Bennett TL, Moore R, Forster J, **Tawfik O**. Fibrolamellar hepatocellular carcinoma arising in a background of focal nodular hyperplasia: Report of two cases. J Reproductive Medicine 2005;50:633.
81. Kramer B*, Gao X*, Davis M**, Hall M, Holzbeierlein J, **Tawfik O**. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma. J Am Col Surgeons 2005;201:565.
82. Larsen CG*, Militsakh O, Fan F, **Tawfik O**, Wallace DI. Histoplasmosis presenting as upper airway obstruction: A case report. Otolaryngology Head and Neck Surgery. 2005;132:514.
83. Dileepan K, Johnston T, Li Y, **Tawfik O**, Stechschulte D. Deranged aortic intima thickness, plasma triglycerides and granulopoiesis in SI/SI mice. Mediators of Inflammation. 2005;13:335.
84. Tomita T, Ren Y*, Davis M**, **Tawfik O**. Case report. Phyllodes tumor of borderline malignancy: Seven year follow up with immunohistochemical study. Pathol International 2005; 55:585.
85. Donahue J*, Achcar R*, Karellas M*, Holzbeierlein J, **Tawfik O**. Check Sample: Juxtglomerular Cell Tumor. 2005 ASCP check sample series.
86. Grizzle WE, Bostwick DG, Burke H, **Tawfik O**, et al. Biomarkers in prostate cancer. Education Book, AACR 96th Annu Meeting, Vol., 2005;196-204.
87. Reed G, **Tawfik O**, Casparian MJ. Immunohistochemical analysis of steroid hormone receptors and structural proteins in skin: Effects of aging and hormone status. Journal of Applied Research 2005; vol 5, No 2.: 371-377
88. **Tawfik O**, Kimler BF, Davis M**, Donahue JK*, Persons DL, Fan F, Hagemeister S**, Thomas PA, Connor C, Jewell W, Fabian CF. Automated cellular imaging system (ACIS) vs. fluorescence in situ hybridization in the evaluation of her-2/neu expression in primary breast carcinoma. Histopathology. 2006;48:258.
89. Weroha SJ*, Li SA, **Tawfik O**, Li JJ. Overexpression of cyclin D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats. Carcinogenesis. 2006;27:491.

90. Langat DK*, Platt SJ, **Tawfik O**, Fazleabas AT, Hunt JS. Differential expression of human leukocyte antigen-G (HLA-G) messenger RNAs and proteins in normal human prostate and prostatic adenocarcinoma. *Journal of Reproductive Immunology*. 2006;71:75.
91. Buchman L*, Larsen C*, Tsue T, Pollack A, **Tawfik O**, Sykes K, Hoover L. Endoscopic techniques and resection of anterior skull base and paranasal sinus malignancies. *Laryngoscope*. 2006;116:1749.
92. Fan F, Namiq AL, **Tawfik O**, Thomas P. Proposed prognostic score for breast carcinoma on fine needle aspiration based on nuclear grade, cellular dyscohesion and bare atypical nuclei. *Diagnostic cytopathology*. 2006;34:542.
93. Hsu HHT, **Tawfik O**. Mechanisms of focal calcification in rabbit aortas: Role of calcifying vesicles. *Journal of Investigative Medicine*, 2006; 54:402.
94. Sun A, **Tawfik O**, Gayed B*, Thrasher JB, Hoestje S, Li C, Li B. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. *Prostate*. 2007; 67:203.
95. Stasik C*, **Tawfik O**. Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation (malignant triton tumor). *Arch Pathol Lab Med*. 2006; 130:1878.
96. Kramer B*, Shideler B*, Danley M**, Kimler BF, Holzbeierlein J, **Tawfik O**. Prognostic significance of CD44, PDGF receptor- α and COX-2 expression in renal cell carcinoma. *Arch Path and Lab Med* 2007; 131:261.
97. Fan F, Smith W, Wang X*, Jewell W, Thomas PA, **Tawfik O**. Myoepithelial Carcinoma of the Breast arising in an Adenomyoepithelioma: A Case Report and Review of the Literature. *The breast J* 2007; 13: 203.
98. Cui W*, Zhang D, **Tawfik O**. Thymoma with extensive necrosis. A case report and review of literature. *Pathologica* 2006; 98:652.
99. Liu X*, Inciardi M, Bradley JP, Fan F, Thomas P, Smith W, **Tawfik O**. Microcalcifications of the breast: size matters! A mammographic-histologic correlation study. *Pathologica* 2007; 99:5.
100. **Tawfik O**, Kimler BF, Davis M**, Stasik C*, Lai SM, Mayo MS, Fan F, Donahue JK*, Damjanov I, Thomas P, Connor C, Jewell WR, Smith H, Fabian CJ. Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count. *Virchows Arch* 2007; 450:627.
101. McCullough K*, Nguyen H*, Stechschulte D, **Tawfik O**. Ligneous conjunctivitis: a case report with multiorgan involvement. *Histopathology* 2007; 50:511.

102. Dhillon NK*, Sui Y, Pinson D, Li S, Dhillon S, **Tawfik O**, Callen S, Nemon O, Narayan O, Buch S. Upregulation of expression of platelet-derived growth factor and its receptor in pneumonia associated with SHIV-infected macaques. *AIDS* 2007; 21:307.
103. Dhillon NK*, Pinson D, Dhillon S*, **Tawfik O**, Danley M**, Davis M**, Nemon O, Mayo M, Kumar A, Tsai YJ, Kumar A, Buch S. Bleomycin treatment causes enhancement of virus replication in the lungs of SHIV-infected macaques. *Am J Physiol Lung Cell Mol Physiol.* 2007; 292:L1233.
104. Dhar G, Mayo M, Tawfik O, Vanvelhuizen P, Banerjee S. Gain-of-Oncogenic Function of p53 Mutants induces Invasive Phenotypes in Human Breast Cancer Cells by Silencing CCN5/WISP-2. *Cancer Research* 2008; 68:4580.
105. Banerjee S, Dhar G, Haque I, Kambhampati S, Mehta S, Sengupta K, Tawfik O, Phillips TA, Banerjee SK. CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. *Cancer res* 2008; 68:7606.
106. Kong B, Lash L, Luyendyk J, Tawfik O, Guo G. "FXR-deficiency Induces Non-alcoholic Steatohepatitis in LDLr-knockout Mice Fed a High-fat Diet. *J Pharmacol Experimental Therapeutics* 2009; 328:116.
107. Zhu Q, Youn H, Tang J, **Tawfik O**, Dennis K*, Terranova PF, Du J, Thrasher B, Li B. Phosphoinositide 3-OH kinase p85a and p110B are essential for androgen receptor transactivation and tumor growth in prostate cancers. *Oncogene* 2008; 27:4569.
108. Stevens E*, Kimler BF, Davis M**, Fan F, Thomas P, Wang X-Y*, Damjanov I, **Tawfik O**. A Newly Proposed Semi-Automated Method of Grading Invasive Lobular Carcinoma. A Unifying Concept and Correlation with Prognostic Markers and Patient Survival. *Annals of Clinical and Laboratory Science* 2009, 39:25.
109. Bass R*, Perry B*, Langenstroer P, Thrasher JB, Dennis KI*, **Tawfik O**, Holzbeierlein J: Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. *J Urology*, 2008 (Epub ahead of print).
110. Krishnan L, Jewell WR, Connor C, **Tawfik O**, Alvarez-Farinetti A, Wang F, Reddy E, Thadikona S, Krishnan EC, Kimler BF. Breast Conservation Therapy with Tumor Bed Brachytherapy Alone in Stage I Breast Cancer: Results of a Phase II Trial. *Kansas Journal of Medicine* 2009, 2:33.
111. Wang XY, Jakowski J, **Tawfik O**, Thomas PA, Fan F. Angiosarcoma of the breast: a clinicopathologic analysis of cases from the last 10 years. *Ann Diagn Pathol* 2009 (Epub ahead of print)
112. Wang J*, Gardner BM, Lu Q, Rodova M, Woodbury BG, Yost JG, Roby KF, Pinson DM, **Tawfik O**, Anderson HC. Transcription factor NFAT1 deficiency causes osteoarthritis through dysfunction of adult articular chondrocytes. *J Pathology* 2009 (Epub ahead of print)

113. **Tawfik O**, Redick M. Integrated radiology/pathology service for breast cancer. Multidisciplinary web conferencing pilot project offers insight on current testing protocols. *Critical Values* 2009, 2: 23.
114. Girod A, Sykes K, Jorgensen J*, **Tawfik O**, Tsue T. Acellular dermis compared to skin grafts in oral cavity reconstruction. *Laryngoscope* 2009 (Epub ahead of print).

2. **Manuscripts in Press:**

115. Templeton KJ, **Tawfik O**, Raveill T*, Lai S-M. The use of Thallium Chloride imaging in the evaluation of cartilage tumors. *J Bone and Joint Surgery* (accepted)
116. Thomas J*, **Tawfik O**. Recent advances in the diagnosis of renal cell carcinoma. *Current Diagnostic Pathology* (in press)
117. Dennis K*, Tawfik O. Small cell neuroendocrine carcinoma of the cervix, check Sample. *Am Soc Clin Pathol*, 2009 (in press)
118. Cabrera C*, Shanyder Y, Tawfik O, et al. Use of p53 and Ki67 as biomarkers in head and neck squamous cell carcinomas. (submitted)
119. Dunlay RP*, Haynes NG*, Tawfik O, Hodges J*, Arnold PM. Pigmented villonodular synovitis of the thoracic spine: Case report and review of the literature. *Coluna/Columna* (submitted).
120. Means M, **Tawfik O**, Fan F, Krebill R. Evaluating patterns of clinical treatment and follow-up in patients with a cytologic diagnosis of atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion. *Cancer Cytopathology* (in revision)
121. Smith D*, Tan X, **Tawfik O**, Milne G, Stechschulte D, Dileepan K. Aortic atherosclerotic plaque development and Thromboxana A2 production are increased in female Apolipoprotein E-null mice. *Exp Biol Med* (in revision).
122. Lalich D*, **Tawfik O**, Chapman J, Fraga G. Cutaneous metastasis of ovarian carcinoma with shadow cells mimicking a primary matrical neoplasm,. *J Cut Pathology* (Submitted).

3. **Manuscripts in preparation:**

1. Hamidpour S*, Kimler BF, Davis M**, Hull S*, Fan F, Khan Q, Thomas P, **Tawfik O**. A comparative histopathological and clinical study of “triple negative” invasive mammary carcinomas in African American and Caucasian women.
2. Liu X*, Kimler BF, Davis M**, Fan F, Thomas P, **Tawfik O**. Is measurement of Ki67 in axillary lymph node metastasis of breast cancer useful?

3. **Tawfik O**, O'Neil MF*, Davis M**, Cunningham MT, Skikne B, Chapman KD**. A newly proposed iron stain quantitation method in bone marrow smears using an automated cellular imaging system.

* Resident or medical student ** Technician

5. **Other Publications:**

Book review:

Contemporary Issues in Surgical Pathology Vol 19. Tumors and Tumor like Lesions of the Uterine Corpus and Cervix. (Ed. PB Clement, RH Young) Churchill Livingstone, 1994

Atlas of Cervical Pathology 1.0 CD-ROM. (Ed. SJ Robboy, HJ Norris) Chapman & Hall, International Thomson Publishing, 1996

Dallenbach-Hellweg G, Poulsen H: Atlas of Endometrial Histopathology, Second Edition. Springer-Verlag Berlin Heidelberg New York, 1996

Lawrence WD and Abdul-Karim FW: Differential Diagnosis in Pathology. Gynecologic and Obstetrical Disorders, Volume 1, Williams & Wilkins, Baltimore, Maryland 1998

Luesley DM, Shafi MI, Jordan JA: Handbook of Colposcopy, 2nd Edition. Arnold, 2002. Oxford University Press, Inc.

BOOK Chapters:

Anatomic Pathology Chapter in Jacobs and DeMott Laboratory Test Handbook, 5th Edition (Ed DS Jacobs, WR DeMott, DK Oxley) 2001 LEXI_COMP's Clinical Reference Library. pp 59-60.

Cancer Grading Manual: Chapters 2 and 3 Editor Ivan Damjanov and Fang Fan, Springer 2007

Atlas of Gynecologic Pathology. Editors Ossama Tawfik, Ivan Damjanov and Fang Fan, McGraw Hill Medical, 2007

P. Published Abstracts:

1. **Tawfik O**, Bodensteiner D, Sinor LT, Rachel JM, Bayer WL, Plapp FV. A simplified solid phase platelet crossmatch. Transfusion 23:414, 1983
2. **Tawfik O**, Hunt JS, Wood GW. Immunomodulation by murine uterine macrophages. Fed Proc 44:1712, 1985
3. **Tawfik O**, Hunt JS, Wood GW. A major soluble suppressor factor produced by uterine cells during pregnancy is prostaglandin E₂ (PGE₂). J Reprod Immunol 9, Suppl: 126, 1986

4. **Tawfik O**, Hunt JS, Wood GW. A non-prostaglandin decidual cell factor suppresses late stages of MLRs. *Am J Reprod Immunol Microbiol* 14:13, 1987
5. Sagrillo C, **Tawfik O**, Johnson DC, Dey SK. Leukotrienes are necessary for decidualization in the rat. *Biol Reprod* 36 Suppl 1:156, 1987
6. **Tawfik O**, Dey SK. Biphasic effect of dexamethasone on uterine prostaglandins (PGs) and leukotrienes (LTs) in rats. *Biol Reprod* 38, Suppl. 1:187, 1988
7. McGregor D, **Tawfik O**. Lipohyperplasia of ileocecal valve. *Am J Clin Path* 93:440, 1990
8. **Tawfik O**, McLemore J*, Choudhuri R*, Wood GW. Localization of immune cells and cytokines in the endometrium during the menstrual cycle. *Biol Reprod* 44, Suppl 1:86, 1991
9. **Tawfik O**, McLemore J*, Wood GW. Immunolocalization of growth factors in the human endometrium during the menstrual cycle. *Mod Path* 5: 69A, 1992
10. Jarmer S*, **Tawfik O**, Collins J. Immunoreactivity of PCNA, p53, cytokeratins and EMA in thyroid neoplasms. *Am J Clin Path* 100: 315, 1993
11. Poole E*, Collins J*, **Tawfik O**. P53, PCNA and cathepsin D as prognostic indicators in malignant melanoma. *Am J Clin Path* 102: 521, 1994
12. Venuti S, Collins J, **Tawfik O**. Localization of endometrial immune cells in chronic endometritis. *Am J Clin Path* 102: 531, 1994
13. Freidman EJ*, **Tawfik O**, Persons DL. Amplification and overexpression of HER-2/NEU oncoprotein in endometrial carcinomas: Correlation of fluorescent in situ hybridization and immunohistochemical methods on formalin-fixed tissue. *Am J Clin Path* 106: 415, 1996
14. Ault K, **Tawfik O**, Smith-King M*, Gunter J. Production of interleukin 1 beta in response to chlamydial infection in an in vitro model of the human fallopian tube. *Infec Dis Obstet Gynecol* 4:203, 1997
15. Lu D*, **Tawfik O**, Pantaziz C. Altered expression of CD44 and variant isoforms in human adenocarcinoma of the endocervix during progression. *Am J Clin Path* 108: 1997
16. Munyer P*, Collins J**, Cansler M**, **Tawfik O**. Cyclin A as a proliferation marker for breast carcinoma; An Immunohistochemical study comparing MIB-1 and Cyclin A. *Am J Clin Pathol* 110, 1998
17. Gunter J*, Smith-King M*, Collins J**, **Tawfik O**. Vulvodynia: in situ hybridization analysis for human papillomavirus. *Prim Care Update Ob Gyns* 1:152, 1998
18. Weed JC, Shoup B*, **Tawfik O**. Small cell carcinoma of the cervix: a clinical study of 15 patients and review of the literature. *Prim Care Update Ob Gyns* 1:159, 1998

19. Garrigues N, **Tawfik O**, Goldstein G. Metastatic basal cell carcinoma with Merkel cell carcinoma features. *Dermatol Surg* 24, 481, 1998
20. Fan F*, **Tawfik O**, Nothnick W, Thomas P, Collins J**. Altered CD44 expression in patients with endometriosis. *American Journal of Clinical Pathology* 112: 544, 1999
21. Ren Y*, Munyer P*, **Tawfik O**, Cansler M**, Collins J**. Cyclin A and MIB-1 expression as prognostic indicators in astrocytic tumors utilizing image-based cell analysis system (CAS-200). *Am Soc Clin Pathologists*. New Orleans, Louisiana Oct 1999
22. Lu D*, Means M, **Tawfik O**, Thomas PA. Cerebral spinal fluid cytology using ThinPrep preparations: comparison with cytopsin, *Acta Cyto.*, 1999
23. Ren Y*, Means M, **Tawfik O**, Thomas PA. Kansas University Medical Center (KUMC) Experience with Atypical Squamous Cells of Undetermined Significance (ASCUS), Favor Reactive Vs. Favor Dysplasia Rates: Comparison of ThinPrep and Conventional Pap Smears. *Acta Cytol.*, 1999
24. Persons D, Cansler M**, Runnebaun S, Collins J**, Borelli K, **Tawfik O**. Comparison of fluorescence in situ hybridization and immunohistochemistry for evaluation of Her-2-neu. *Assoc Mol Path* 1999
25. Wang F*, Krishnan L, **Tawfik O**, Ren Y*, Kimler B, Miller R, Chapman J, Weed J. Prognostic significance of apoptosis in cancer of the cervix . *Radiation Research Soc 47th Annual Meeting* 2000
26. Templeton KJ, **Tawfik O**, Raveill T, Lai S-M. The use of Thallium Chloride imaging in the evaluation o cartilage tumors. *Musculoskeletal Tumor Soc. Washington DC, 1998 poster presentation Amesterdon, Holland, 1999. Sarcoma Vol 3, 2, 1999*
27. Gatalica Z, Lucio E, Finkelstein S, Palazzo J, **Tawfik O**. The role of p53 mutation and Ki-67 proliferation index in the diagnosis and progression of phylloides tumor of the breast. *Modern Pathol* 1999; 12:21A.
28. Persons DL, Cansler M**, Runnebaun S, Collins J**, Borelli K, **Tawfik O**. Comparison of fluorescence in situ hybridization and immunohistochemistry for evaluation of HER-2/neu in breast carcinoma. *Am J Pathology* Nov 1999
29. Gunter J, Ranallo L, **Tawfik O**. Inflammatory streptococcal vaginitis. *Infect Dis Soc Ob/Gyn* 1998
30. Wong S, Fan F*, **Tawfik O**, Sonnino R. Muscular hamartoma of the breast in a pediatric patient: A case report and review of the literature. *Am Acad Ped Section on Surgery* 1999/2000
31. Fabian C, Kimler B, Anderson J**, **Tawfik O**, Mayo M, O'Saughnessy J, Albain K, Burak W, Ihde J, Ganz P, Budd G, Lawrence J. Phase I biomarker and toxicity evaluation of LY353381 (a

- 3rd generation selective estrogen receptor modulator, SERM) in breast cancer. ASCO, New Orleans, 2000 Proc Am Soc Clin Oncol 19:75a, 2000.
32. Ellis RJ*, Kimler B, Fabian C, **Tawfik O**, Mehta R, Kysthoobayeva A, Fruehauf J. Angiogenesis index (AI) is associated with early recurrence in patients presenting with primary breast cancer. 23rd Annual San Antonio Breast Cancer Symposium 2000. Breast Cancer Res Treat 64:101, 2000
 33. Lindsley H, **Tawfik O**, Smith D, Collins J**, Colbert N, Hunt J. Apoptosis in rheumatoid synovium. Expression of Trail and its receptors DR4 and DR5. Rheumatology meeting 2001 (accepted)
 34. Templeton KT, Raveill T*, **Tawfik O**. Thallium 201 uptake in chondroid lesions. Connective Tissue Oncology Soc 2001
 35. Hsu HHT, **Tawfik O**, Sun F. Is calcification closely associated with ossification during atherosclerosis? J Bone Mineral Res 2001: 16:S323
 36. Hsu HHT, **Tawfik O**, Sun F. Effects of lectins on calcification by vesicles isolated from aortas of cholesterol-fed rabbits. Atherosclerosis 151:77
 37. Hsu HHT, **Tawfik O**, Sun F. Mechanisms of calcification by vesicles from rabbit atherosclerotic aortas. FASEB 2001, A246
 38. Hsu HHT, Camacho N, **Tawfik O**, Sun F. Effects of high cholesterol feeding on arterial and vesicle calcification by vesicles using rabbit as a model. Int Bone and Mineral Res, Madrid, Spain, May 2001.
 39. Sonnino RE, Cross RS**, **Tawfik O**. Mediators of ischemia in preserved intestinal grafts. VII International Small Bowel Transplant Symposium. Transplant Proc 2002, Sept, 2001 Stockholm, Sweden (accepted)
 40. Fang F, Ren Y*, Thomas P, **Tawfik O**. The value of differential and coordinate expression of cytokeratins 7 and 20 in the evaluation of metastatic carcinoma of unknown origin in Thinprep cytology. 49th Scientific Meeting of the Am Soc Cytopath Nov 2001
 41. Connor CS, **Tawfik O**, Joyce AJ*, Davis MK**, Mayo MS, Jewell WR. A comparison of prognostic markers obtained on Image-Guided breast biopsies and final surgical specimens. Am College of Surgeons meeting 2002.
 42. Pantazis CG, Iczkowski KA*, McGregor D, **Tawfik O**. Telomerase subunit hTERT immunoreactivity in prostate cancer. Modern Pathol 2002; 15:176A.
 43. Li Y*, Battaglia T*, Davis M**, Hankins L, Hagemeister S**, Arthur T**, **Tawfik O**, Persons DL. Comparison of Fluorescence In situ Hybridization and Immunohistochemistry for HER-2/neu Detection in Breast Carcinoma. American Journal of Clinical Pathol 2002, 118:641.

44. Hsu HHT, **Tawfik O**, Sun F. Temporal and spatial development of cholesterol-induced atherosclerotic calcification in juvenile rabbits. *Atherosclerosis* (in press)
45. Girgis KR, Danley M**, Olson NY, **Tawfik O**, Stechschulte DJ. Expression of keratinocyte growth factor (KGF) is upregulated in nasal polyp disease. *Am Acad Allergy, Asthma and Immunol mtg 2003* (accepted)
46. Fan F, **Tawfik O**, Namiq AL, Davis MK**, Connor CS, Jewell WR, Thomas PA. Comparison of prognostic markers in primary breast carcinomas and their respective axillary lymph node metastases. *US and Can Acad of Pathologists mtg, Mar 2003*
47. **Tawfik O**, Donahue JK*, Fan F, Davis M, Persons DL, Connor C, Jewell W, Kimler BF, Fabian CF. Comparison of immunohistochemistry (IHC) by automated cellular imaging system (ACIS) vs fluorescence in situ hybridization (FISH) in the evaluation of Her-2/neu expression in primary breast carcinoma. *Proc Am Soc Clin Oncol 22:902, 2003* (abstract 3626).
48. Imkie M*, **Tawfik O**, Davis M**, Danley M**, Kirchoff J*, Fabian CF, Montgomery-Rice V, Terranova P. Cyclooxygenase-2 and MIB-1 in normal and pathologic ovaries: Correlations with ovulation, follicular cysts and cancer. *USCAP, MAR 2003* (accepted)
49. **Tawfik O**, Donahue JK*, Fan F, Davis M**, Persons DL, Connor C, Jewell W, Kimler BF, Fabian CF. Comparison of immunohistochemistry (IHC) by automated cellular imaging system (ACIS) Vs fluorescence in-situ hybridization (FISH) in the evaluation of HER-2/neu expression in primary breast carcinoma. *ASCO, July 2003* (accepted)
50. Namiq A, Fan F, Thomas PA, **Tawfik O**. Axillary lymph node dissection after positive sentinel lymph node biopsy for metastatic breast carcinoma. *Annual meeting of the United States and Canadian Academy of Pathology, Vancouver, Canada 2004*
51. **Tawfik O**, Fan F, Davis M**, Damjanov I, Thomas P, Kimler B. A new semi-automated method of grading breast carcinoma based on a multivariant analysis of 527 cases. *Modern Pathology 2004; 15:51A abstract #201.*
52. Namiq A, Fan F, **Tawfik O**, Thomas PA, Atkinson B. Suspicious lesions in thyroid aspirates: Can we be more specific? *Annual meeting of the American Society of Cytopathology. Chicago, ILL 2004.*
53. Vancura R*, Fan F, Connor C, Namiq A, Thomas PA, **Tawfik O**. Histologic and biomarkers assessment of residual breast carcinomas in surgical specimens after neoadjuvant chemotherapy. *Annual meeting of the United States and Canadian Academy of Pathology, San Antonio, TX 2005*
54. Namiq A, Fan F, **Tawfik O**, Thomas P. Expression of p27 in primary versus metastatic breast carcinomas: Its prognostic significance and relation to other prognostic markers. *Annual meeting of the United States and Canadian Academy of Pathology, San Antonio, TX 2005*

55. Gao X*, Kramer B* , Davis M**, Hall M, Holzbeierlein J, **Tawfik O**. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma. Annual meeting of the United States and Canadian Academy of Pathology, San Antonio, TX 2005
56. Petroff BK, **Tawfik O**, Gum SL, Nynca A, Valdez KE, Kimler BF, Fabian CJ. Development of a rat model of simultaneous mammary and ovarian cancer: Expression of putative early markers of cancer risk and progression. Proc Am Assoc Cancer Res 46, 2005
57. **Tawfik O**, Davis M**, Lai, S-M, Fan F, Donahue J*, Thomas P. The Value of Digital Microscopy in Enhancing Accuracy and reliability in Grading Breast Carcinomas. The Newly Proposed KU Grading System and Its Correlation with patients' Survival. Modern Pathology 2005; 18:52A abstract #229.
58. Kimler BF, Fabian CJ, Anderson JR, **Tawfik O**, et al. Breast cancer chemoprevention phase IB evaluation of biomarker modulation by celecoxib, a selective cyclooxygenase 2 inhibitor. San Antonio Breast Cancer Symposium, Dec, 2006
59. Gatalica Z, Lee L, Hatcher L, Palazzo J, Bilalovic N, Adegboyega A, **Tawfik O**. Pure apocrine carcinomas of the breast overexpress EGFR and have increased EGFR gene dosage to polysomy of chromosome 7. Annual meeting of the United States and Canadian Academy of Pathology, San Diego, CA 2006
60. **Tawfik O**, O'Neil MF*, Davis M**, Cunningham MT, Skikne B, Chapman KD**. A newly proposed iron stain quantitation method in bone marrow smears using an automated cellular imaging system. Am Soc Clin Pathology annual mtg, Oct 2006
61. O'Dea AP*, Hamidpour S*, Kimler BF, **Tawfik O**, Shaffie R, Sharma P, Fabian CJ, Khan QJ. Lymphovascular invasion but not EGFR expression is prognostic in triple negative breast cancer. ASCO mtg, 2007.
62. **Tawfik O**, Peterson L, Parker L, Davis M**, Chapman J, Ma J*. Correlation between Extreme Drug Resistance Assay and Response to Chemotherapy in Patients with Epithelial Ovarian Cancer. ASCO mtg 2007
63. Ting AY, Xue Q, **Tawfik O**, Kimler BF, Fabian CJ, Petrof BK. Cancer biomarker expression in a preclinical model for simultaneous chemoprevention of breast and ovarian cancer. 2007
64. Cabrera C*, **Tawfik O**, Sykes K, Champion T, et al. Use of p53 and ki67 as biomarkers in head and neck squamous cell carcinoma. 2007
65. Hamidpour S*, Kimler BF, Davis M**, Hull S*, Fan F, Khan Q, Thomas P, **Tawfik O**. A comparative histopathological and clinical study of “triple negative” invasive mammary carcinomas in African American and Caucasian women. Annual meeting of the United States and Canadian Academy of Pathology, Denver, CO 2007

66. Liu X*, Kimler BF, Davis M**, Fan F, Thomas P, **Tawfik O**. Is measurement of Ki67 in axillary lymph node metastasis of breast cancer useful? Annual meeting of the United States and Canadian Academy of Pathology, Denver, CO 2008
67. Thompson L, **Tawfik O**, Templeton K, Tancabelic J, Pinson D, Anderson HC, Keighley J, Garimella R. The Dose Response of Vitamin D on Proliferation and Differentiation in Human Annual Research Conference of American Institute of Cancer Research 2008.
68. Means M, **Tawfik O**, Fan F, Krebill R. Evaluating patterns of clinical treatment and follow-up in patients with a cytologic diagnosis of atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion. *Cancer (Cancer Cytopathol)*. 2008; 114:390.
69. Montgomery JA, **Tawfik O**, Williamson T, Buch S, O'brien-Ladner A. Prevalence of otherwise unexplained pulmonary arteriopathy in AIDS patients at autopsy. *Chest* Oct, 2008 (the American College of Chest Physicians)
70. Huang C, Williamson S, Van Veldhuizen P, Hsueh C, Allen A, Smith H, Mayo M, **Tawfik O**, Uypeckcuat A, Kelly K. PDGFR inhibition using Imatinib combined with Docetaxel, a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer, preliminary efficacy results. ASCO meeting 2008
71. **Tawfik O**, Garimella R, Tancabelic J, Keighley J, Pinson D, Khan Q, Templeton K. Retrospective immunohistochemical study of VDR, RXR, Ki-67 and Bcl-2 expression in primary and metastatic osteosarcoma. *J Clin Oncol* 2009;27 (suppl; abstr e21516).
72. **Tawfik O**, Kimler BF, Fan F, McGregor D. Variables impacting lymph node assessment in colorectal resection specimens removed for adenocarcinoma. *Mod Pathol* 22, suppl 1, 2009 abstract #673, page 150A
73. O'Neil M, Madan R, **Tawfik O**, Thomas P, Damjanov I, Fan F. Lobular carcinoma in situ/atypical lobular hyperplasia on breast biopsies: does it warrant surgical excision? *Mod Pathol* 22, suppl 1, 2009 abstract #265, page 61A

* Resident or medical student

** Technician

Q. Poster Exhibits:

1. **Tawfik O**, Bodensteiner D, Sinor LT, Rachel JM, Bayer WL, Plapp FV. A simplified solid phase platelet crossmatch. November, 1982, New York, American Association of Blood Banks Meeting
2. **Tawfik O**, Hunt JS, Wood GW. Immunomodulation by murine uterine macrophages. Spring, 1985, Los Angeles, Federation Proceedings Meeting

3. **Tawfik O**, Hunt JS, Wood GW. A major soluble suppressor factor produced by uterine cells during pregnancy is prostaglandin E₂ (PGE₂). July, 1986, Toronto, Ontario, Canada, the 3rd International Congress of Reproductive Immunology
4. McGregor D, **Tawfik O**. Lipohyperplasia of ileocecal valve. March, 1990, San Francisco, California, The American Society of Clinical Pathologists
5. **Tawfik O**, McLemore J*, Choudhuri R*, Wood GW. Localization of immune cells and cytokines in the endometrium during the menstrual cycle. July, 1991, Vancouver, Canada, Society for the Study of Reproduction
6. **Tawfik O**, McLemore J*, Wood GW. Immunolocalization of growth factors in the human endometrium during the menstrual cycle. March, 1992, Atlanta, Georgia, United States and Canadian Academy of Pathologists
7. Jarmer S*, **Tawfik O**, Collins J**. Immunoreactivity of PCNA, p53, cytokeratins and EMA in thyroid neoplasms. March, 1993, Orlando, Florida, The American Society of Clinical Pathologists
8. Poole E*, Collins J**, **Tawfik O**. P53, PCNA and cathepsin D as prognostic indicators in malignant melanoma. October, 1994, Washington, DC, The American Society of Clinical Pathologists
9. Venuti S*, Collins J**, **Tawfik O**. Localization of endometrial immune cells in chronic endometritis. October, 1994, Washington, DC, The American Society of Clinical Pathologists
10. Freidman EJ*, **Tawfik O**, Persons DL. Amplification and overexpression of HER-2/NEU oncoprotein in endometrial carcinomas: Correlation of fluorescent in situ hybridization and immunohistochemical methods on formalin-fixed tissue. October, 1996, San Diego, California, The American Society of Clinical Pathologists
11. Ault K, **Tawfik O**, Smith-King M*, Gunter J*. Production of interleukin 1 beta in response to chlamydial infection in an in vitro model of the human fallopian tube. International Symposium on Immunopathogenesis of Chlamydia Infections. Dec 7, 1996 New York, NY
12. Kamel S, Zeiger S, Zalles C, **Tawfik O**, Kimler B, Simon C, Fabian CJ. p53 protein overexpression and gene mutation in a group of women at high risk for breast cancer. February, 1997, Amelia Island Florida, The second Annual Multi-disciplinary Symposium on Breast Diseases.
13. Lu D*, **Tawfik O**, Pantaziz C. Altered expression of CD44 and variant isoforms in human adenocarcinoma of the endocervix during progression. September 1997. Philadelphia, Pennsylvania. The American Society of Clinical Pathologists

14. Gunter J, Ranallo L, **Tawfik O**. Inflammatory streptococcal vaginitis. Third Annual Conference on Women's Health Care Issues. May, 1998, New Orleans, Louisiana, International Infectious Disease Society of Obstetrics and Gynecology
15. Gunter J, Smith-King M*, Collins J**, **Tawfik O**. Vulvodynia: In-situ hybridization analysis of human papillomavirus. May, 1998, New Orleans, Louisiana, ACOG 46th Annual Meeting.
16. Weed J, Shoup B*, **Tawfik O**. Small cell undifferentiated (neuroendocrine) carcinoma of the cervix. A clinical study of 15 patients and review of the literature. May, 1998, New Orleans, Louisiana, AGOG 46th Annual Meeting
17. Joseph AK, Garrigues N, **Tawfik O**, Goldstein G. Metastatic basal cell carcinoma with Merkel cell carcinoma features. May, 1998, Portland, Oregon, Annual Meeting of the American College of Mohs Micrographic Surgery and Cutaneous Oncology
18. Munyer P*, Collins J**, Cansler M**, **Tawfik O**. Cyclin A as a proliferation marker for breast carcinoma; An Immunohistochemical study comparing MIB-1 and Cyclin A. Oct, 1998, Washington DC, American Society of Clinical Pathologists.
19. Fan F*, **Tawfik O**, Nothnick W, Thomas P, Collins J**. Altered CD44 expression in patients with endometriosis. Oct, 1999, New Orleans, Louisiana, American Society of Clinical Pathologists.
20. Persons DL, Cansler M**, Runnebaun S, Collins J**, Borelli K, **Tawfik O**. Comparison of fluorescence in situ hybridization and immunohistochemistry for evaluation of HER-2/neu in breast carcinoma. November, 1999, Association for Molecular Pathology, American Journal of Pathology
21. Gatalica Z, Lucio E, Finkelstein S, Palazzo J, **Tawfik O**. The role of p53 mutation and Ki-67 proliferation index in the diagnosis and progression of phylloides tumor of the breast. March, 1999, San Francisco, California, United States and Canadian Academy of Pathologists Annual Meeting
22. Ren Y*, Munyer P*, **Tawfik O**, Cansler M**, Collins J**. Cyclin A and MIB-1 expression as prognostic indicators in astrocytic tumors utilizing image-based cell analysis system (CAS-200). October, 1999, New Orleans, Louisiana, American Society of Clinical Pathologists
23. Hsu HHT, **Tawfik O**, Sun F. Effects of lectins on calcification by vesicles isolated from aortas of cholesterol-fed rabbits. *Atherosclerosis* 2000; 151:77
24. Fabian C, Kimler B, Anderson J*, **Tawfik O**, Mayo M, O'Saughnessy J, Albain K, Burak W, Ihde J, Ganz P, Budd G, Lawrence J. Phase I biomarker and toxicity evaluation of LY353381 (a 3rd generation selective estrogen receptor modulator, SERM) in breast cancer. New Orleans, 2000, ASCO

25. Ellis RJ*, Kimler B, Fabian C, **Tawfik O**, Mehta R, Kysthoobayeva A, Fruehauf J. Angiogenesis index (AI) is associated with early recurrence in patients presenting with primary breast cancer. 23rd Annual San Antonio Breast Cancer Symposium 2000.
26. Hsu HHT, **Tawfik O**, Sun F. Mechanisms of calcification by vesicles from rabbit atherosclerotic aortas. FASEB 2001, A246
27. Templeton KT, Raveill T*, **Tawfik O**. Thallium 201 uptake in chondroid lesions. Connective Tissue Oncology Soc 2001
28. Hsu HHT, Camacho N, **Tawfik O**, Sun F. Effects of high cholesterol feeding on arterial and vesicle calcification by vesicles using rabbit as a model. Int Bone and Mineral Res, Madrid, Spain, May 2001.
29. Hsu HHT, **Tawfik O**, Sun F. Is calcification closely associated with ossification during atherogenesis? J Bone & Mineral Res 16, S323.
30. Lu D*, Thomas P, **Tawfik O**. Cerebral spinal fluid cytology using ThinPrep preparations: comparison with cytopsin. Nov, 2000, American Society of Cytology Annual Meeting
31. Connor CS, **Tawfik OW**, Joyce AJ*, Davis MK**, Mayo MS, Jewell WR. A comparison of prognostic markers obtained on Image-Guided breast biopsies and final surgical specimens. Surgery meeting, 2002
32. Pantazis CG, Iczkowski KA*, McGregor D, **Tawfik O**. Telomerase subunit hTERT immunoreactivity in prostate cancer. United States and Canadian Academy of Pathologist Annual Meeting, Chicago, Ill, Feb, 2002
33. Hsu HHT, **Tawfik O**, Sun F. Temporal and spatial development of cholesterol-induced atherosclerotic calcification in juvenile rabbits. Am Soc Bone and Mineral Research, San Antonio Sep 2002
34. Girgis K, Danley M, Olson NY, **Tawfik O**, Stechschulte DJ. Expression of keratinocyte growth factor (KGF) is upregulated in nasal polyp disease. Am Acad Allergy, Asthma and Immunol mtg 2003 (accepted)
35. Fan F, **Tawfik O**, Namiq AL, Davis MK, Connor CS, Jewell WR, Thomas PA. Comparison of prognostic markers in primary breast carcinomas and their respective axillary lymph node metastases. US and Can Acad of Pathologists mtg, Mar 2003
36. **Tawfik O**, Donahue JK*, Fan F, Davis M**, Persons DL, Connor C, Jewell W, Kimler BF, Fabian CF. Comparison of immunohistochemistry (IHC) by automated cellular imaging system (ACIS) Vs fluorescence in-situ hybridization (FISH) in the evaluation of HER-2/neu expression in primary breast carcinoma. 4th International Symposium on Hormonal carcinogenesis, June 2003 Valencia, Spain

37. Casillan A, Wood J, **Tawfik O**, Udobi K, Schloerb P, reaction of the intestine to enteral feedings. Aspen 2003
38. Imkie M*, **Tawfik O**, Davis M**, Danley M**, Kirchoff J*, Fabian CF, Montgomery-Rice V, Terranova P. Cyclooxygenase-2 and MIB-1 in normal and pathologic ovaries: Correlations with ovulation, follicular cysts and cancer. Annual meeting of the United States and Canadian Academy of Pathology, Washington, DC 2003
39. Namiq A, Fan F, Thomas PA, **Tawfik O**. Axillary lymph node dissection after positive sentinel lymph node biopsy for metastatic breast carcinoma. Annual meeting of the United States and Canadian Academy of Pathology, Vancouver, Canada 2004
40. **Tawfik O**, Fan F, Davis M**, Damjanov I, Thomas P, Kimler B. A new semi-automated method of grading breast carcinoma based on a multivariant analysis of 527 cases. Annual meeting of the United States and Canadian Academy of Pathology, Vancouver, Canada 2004
41. Namiq A, Fan F, **Tawfik O**, Thomas PA, Atkinson B. Suspicious lesions in thyroid aspirates: Can we be more specific? Annual meeting of the American Society of Cytopathology. Chicago, ILL 2004.
42. Vancura R*, Fan F, Connor C, Namiq A, Thomas PA, **Tawfik O**. Histologic and biomarkers assessment of residual breast carcinomas in surgical specimens after neoadjuvant chemotherapy. Annual meeting of the United States and Canadian Academy of Pathology, San Antonio, TX 2005
43. Namiq A, Fan F, **Tawfik O**, Thomas P. Expression of p27 in primary versus metastatic breast carcinomas: Its prognostic significance and relation to other prognostic markers. Annual meeting of the United States and Canadian Academy of Pathology, San Antonio, TX 2005
44. Gao X*, Kramer B*, Davis M**, Hall M, Holzbeierlein J, **Tawfik O**. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma. Annual meeting of the United States and Canadian Academy of Pathology, San Antonio, TX 2005
45. Petroff BK, **Tawfik O**, Gum S, Nynca A, Valdez K, Kimler BF, Fabian CJ. Development of a rat model of simultaneous mammary and ovarian cancer: expression of putative early markers of cancer risk and progression.
46. **Tawfik O**, Davis M**, Lai, S-M, Fan F, Donahue J*, Thomas P. The Value of Digital Microscopy in Enhancing Accuracy and reliability in Grading Breast Carcinomas. The Newly Proposed KU Grading System and Its Correlation with patients' Survival. Modern Pathology 2005; 18:52A abstract #229. Annual meeting of the United States and Canadian Academy of Pathology, San Antonio, TX 2005
47. **Tawfik O**, O'Neil MF*, Davis M**, Cunningham MT, Skikne B, Chapman KD**. A newly proposed iron stain quantitation method in bone marrow smears using an automated cellular imaging system. Am Soc Clin Pathology annual mtg, Oct 2006

48. Microcalcifications of the breast: Size matters! A mammographic-histologic correlation study. Col Am Patholol Annual mtg, Sept 06
49. Kimler BF, Fabian CJ, Anderson JR*, **Tawfik O**, et al. Breast cancer chemoprevention phase IB evaluation of biomarker modulation by celecoxib, a selective cyclooxygenase 2 inhibitor. San Antonio Breast Cancer Symposium, Dec, 2006
50. Carmichael B*, Fan F, Danley M**, **Tawfik O**, Thomas PA. Diagnostic utility of ProEx TMC in evaluating cervical biopsy specimens for high-grade dysplasia. USCAP annual mtg, San Diego, CA 2007.
51. O’Dea AP*, Hamidpour S*, Kimler BF, **Tawfik O**, Shaffie R, Sharma P, Fabian CJ, Khan QJ. Lymphovascular invasion but not EGFR expression is prognostic in triple negative breast cancer. ASCO mtg, 2007.
52. Ting AY, Xue Q, **Tawfik O**, Kimler BF, Fabian CJ, Petroff BK. Cancer biomarker expression in a preclinical model for simultaneous chemoprevention of breast and ovarian cancer. 2007
53. Cabrera C*, **Tawfik O**, Sykes K, Champion T, et al. Use of p53 and ki67 as biomarkers in head and neck squamous cell carcinoma. 2007
54. Hamidpour S*, Kimler BF, Davis M**, Hull S*, Fan F, Khan Q, Thomas P, **Tawfik O**. A comparative histopathological and clinical study of “triple negative” invasive mammary carcinomas in African American and Caucasian women. Annual meeting of the United States and Canadian Academy of Pathology, Denver, CO 2008
55. Liu X*, Kimler BF, Davis M**, Fan F, Thomas P, **Tawfik O**. Is measurement of Ki67 in axillary lymph node metastasis of breast cancer useful? Annual meeting of the United States and Canadian Academy of Pathology, Denver, CO 2008
56. Thompson L, **Tawfik O**, Templeton K, Tancabelic J, Pinson D, Anderson HC, Keighley J, Garimella R. The Dose Response of Vitamin D on Proliferation and Differentiation in Human Osteosarcoma –an In vitro Study. Annual Research Conference of American Institute of Cancer Research 2008.
57. Huang C, Williamson S, Van Veldhuizen P, Hsueh C, Allen A, Smith H, Mayo M, **Tawfik O**, Uypeckcuat A, Kelly K. PDGFR inhibition using Imatinib combined with Docetaxel, a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer, preliminary efficacy results. ASCO meeting 2008
58. O’Neil M, Madan R, **Tawfik O**, Thomas P, Damjanov I, Fan F. Lobular carcinoma in situ/atypical lobular hyperplasia on breast biopsies: does it warrant surgical excision? Mod Pathol 22, suppl 1, 2009 abstract #265, page 61A
59. Means M, **Tawfik O**, Fan F, Krebill R. Evaluating patterns of clinical treatment and follow-up in patients with a cytologic diagnosis of atypical squamous cells cannot exclude high-grade

squamous intraepithelial lesion. 56th Annual Scientific Meeting of the American Society of Cytopathology, Orlando, FL, Nov. 7-11, 2008, poster #65

* Resident or medical student ** Technician

R. Oral Presentations:

1. Scientific papers presented at national and international meetings:

Tawfik O, Hunt JS, Wood GW. A non-prostaglandin decidual cell factor suppresses late stages of MLRs. June, 1987, Indianapolis, Proceedings of the Seventh Annual Symposium of the American Society for the Immunology of Reproduction

Sagrillo C, **Tawfik O**, Johnson DC, Dey SK. Leukotrienes are necessary for decidualization in the rat. July, 1987, Urbana, Illinois, 20th Annual Meeting of the Society for the Study of Reproduction

Tawfik O, Dey SK. Biphasic effect of dexamethasone on uterine prostaglandins (PGs) and leukotrienes (LTs) in rats. August, 1988, Seattle, Washington, 21th Annual Meeting of the Society for the Study of Reproduction

Gunter J, Ranallo L, **Tawfik O**. Inflammatory streptococcal vaginitis. Infect Diseases Society of Obstetrics and Gynecology 1998. New Orleans, Louisiana, 1998

Sonnino RE, Cross RS, **Tawfik O**. Mediators of ischemia in preserved intestinal grafts. VII International Small Bowel Transplant Symposium. 2002, Sept, 2001 Stockholm, Sweden.

Reed GA, **Tawfik O**, Casparian JM. Immunohistochemical analysis of steroid receptors and structural proteins in skin: Effects of aging and hormone status. Prepared for Avon Products, Inc., Suffern, NY 2002

Buchmann L, Larsen C, Tsue TT, Pollack A, **Tawfik O**, Hoover LA. Endoscopic Techniques and Resection of Anterior Skull Base and Paranasal Sinus Malignancies. The Middle and Western Sections of the Triological Society meeting San Diego, CA Feb 2-5, 2006

Gatalica Z, Lee L, Hatcher L, Palazzo J, Bilalovic N, Adegboyega A, **Tawfik O**. Pure apocrine carcinomas of the breast overexpress EGFR and have increased EGFR gene dosage to polysomy of chromosome 7. Annual meeting of the United States and Canadian Academy of Pathology, San Diego, CA 2007

Tawfik O, Kimler BF, Fan F, McGregor D. Variables impacting lymph node assessment in colorectal resection specimens removed for adenocarcinoma. Mod Pathol 22, suppl 1, 2009 abstract #673, page 150A

2. Scientific papers presented at local and regional meetings:

Tawfik O. Uterine cells from allogeneic murine pregnancies suppress mixed lymphocyte reactions (MLR) through prostaglandin E₂ production. January, 1986, Kansas City, Missouri/Missouri Valley Branch, American Society for Microbiology Meeting

Tawfik O. Thymic carcinoma, report of a case and review of the literature. March, 1992, Kansas City, the Kansas City Society of Pathologists

Brown SM, **Tawfik O.** Immunohistochemical characterization of leukocytic subpopulations in chronic endometritis. Annual Resident Research Day & Kermit E. Krants Society Meeting, June, 1996

Smith-King M, Gunter J, **Tawfik O.** Analysis of the relationship between HPV and vulvar vestibulitis. Annual Resident Research Day & Kermit E. Krants Society Meeting, June, 1997

Brown-Shipman SM, Montgomery-Rice VC, **Tawfik O.** The ASCUS Pap smear: A five-year follow-up. Annual Resident Research Day & Kermit E. Krants Society Meeting, June, 1997

Hobart WC, **Tawfik O.** Altered expression of CD44 in human adenocarcinoma of the endocervix. Annual Resident Research Day & Kermit E. Krants Society Meeting, June, 1997

Gunter J, Ranallo L, **Tawfik O.** Inflammatory streptococcal vaginitis. Third Annual Conference on Women's Health Care Issues. International Infectious Disease Society of Obstetrics and Gynecology, Feb, 1998, New Orleans, Louisiana

Joseph A, Garrigues N, **Tawfik O.** Goldstein G. Metastatic basal cell carcinoma with Merkel cell carcinoma Features. 30th Annual Meeting of the American College of Mohs Micrographic and Surgery and Cutaneous Oncology, May 1998, Portland, Oregon

Gunter J, Smith-King M, Collins J, **Tawfik O.** Vulvodynia: In-situ hybridization analysis for human papillomavirus

3. Invited lecturer at local, regional, national and international courses and meetings:

Cytology of pregnancy lecture to the members of the **Heart of America Association of Cytotechnologists** in the spring of 1993, **Invited Speaker**

Endometrial Pathology lecture to the members of the **Heart of America Association of Cytotechnologists**, March 1997, **Invited Speaker**

Fine Needle aspiration cytology of the lung to the members of the **Heart of America Association of Cytotechnologists**, Spring 1998, **Invited Speaker**

Biology of Endocervical Adenocarcinoma- **Invited Speaker**
St. Joseph Medical Center, Kansas City, MO Fall 1999

Developing a Microdissection Laboratory and the Impact of Tissue Microdissection – **Invited Speaker. 5th Annual Masons’ Day. The Kansas Cancer Institute. University of Kansas Medical center.** May 5, 2000

Breast Cancer Treatment- Invited speaker
Spring Research Conference. The University of Kansas and Midwest Research Institute.
April 17, 2001

KCTV 5, health Watch TV Show on the news with Ann Peterson, nationally televised, Kansas City, 2001

ChromaVision, the Automated Cellular Imaging System
University of Nebraska Medical Center - Invited Speaker
February 19, 2002

Target Directed Therapies: The Need for new Pharmacodiagnosics.
Colorado Society of Clinical Pathologists – Invited Speaker
Colorado Springs, Colorado, May 4, 2002

Automated Cellular Imaging System. A new kid on the Block
Heart of America Association of Cytotechnologists, Invited Speaker
Kansas City, KS Sept 2002

Visiting Professor and Lecturer, Faculty of Medicine, Suez Canal University, EGYPT,
Invited Speaker, 7th WHO, Japan and Egyptian Government sponsored International Clinical Pathology Meeting, Ismailia, EGYPT, October 2002

Breast cancer and Her-2 neu.
Invited Speaker, St Mary’s Health Center, St Louis, MO, May 2003

The role a Pathologist Plays in Diagnosing Prostate Cancer.
Invited Speaker, US TOO! International, Inc. Prostate Cancer Survivor Support Group, Kansas Chapter. Kansas City, KS October 16, 2003

Endocervical adenocarcinoma, An update.
Invited Speaker, Kansas City Gynecological Society. Kansas City, KS Feb 26, 2004

Uterine Pathology, An update.
Invited Speaker, Nutrition Institute, Cairo, Egypt, December 2004

Automated Image Analysis.
Invited Speaker, National Research Center, Cairo, Egypt, December 2004

The Use of Robotic (Digital) Telepathology Systems. The New Kid on the Block!!
Invited Speaker, 26th African Health Sciences Congress, Ain Soukhna, Egypt, December 2005

A new, improved, semi-automated way of grading breast cancer.

Invited Speaker, 26th African Health Sciences Congress, Ain Soukhna, Egypt, December 2005

A new, improved, semi-automated way of grading breast cancer.

Invited Speaker, XIV World Congress on Breast Diseases, Zagreb (Croatia), May 2006

Pure Apocrine Carcinoma of the Breast.

Invited Speaker, XIV World Congress on Breast Diseases, Zagreb (Croatia), May 2006

Myoepithelial Carcinoma of the Breast arising in an Adenomyoepithelioma.

Invited Speaker, XIV World Congress on Breast Diseases, Zagreb (Croatia), May 2006

State of the Art Mammopathology Molekulare Biologie-Konsequenzen.

Invited Speaker, 3rd Annual Breast Diseases Conference, Aachen (Germany), Oct 2006

"A New, Semi-Automated Method of Grading Invasive and Non-Invasive Breast Carcinoma Using Image Analysis".

Invited Speaker, Creighton University, Nebraska, Sept 2006

"A New, Semi-Automated Method of Grading Invasive and Non-Invasive Breast Carcinoma Using Image Analysis".

Invited Speaker, Research Medical Center, Kansas City, MO, Sept 2006

"Grading Invasive and Non-Invasive Breast Carcinoma Using Image Analysis"

Invited Speaker, National Arab American Medical Association. 22nd International Medical Convention. New Advances in Early Detection and Management of Cancer Alexandria, Egypt July 1- 3, 2008

"The Role the Pathologist Plays in Diagnosing Prostate Cancer"

Invited Speaker, National Arab American Medical Association. 22nd International Medical Convention. New Advances in Early Detection and Management of Cancer Alexandria, Egypt July 1- 3, 2008

"Lung cancer histopathology-an overview"

Invited Speaker, National Arab American Medical Association. 22nd International Medical Convention. New Advances in Early Detection and Management of Cancer Alexandria, Egypt July 1- 3, 2008

"The Use of Robotic (Digital) Telepathology Systems. The New Kid on the Block!!"

Invited Speaker, National Arab American Medical Association. 22nd International Medical Convention. New Advances in Early Detection and Management of Cancer Alexandria, Egypt July 1- 3, 2008

"Interactive Multidisciplinary Web Conferencing: The Use of the Aperio and PolyCom PVX Systems". **Invited Speaker, Pathology Visions 2008. Digital Pathology Solutions Conference. San Diego, California, October 26-28, 2008.**

"Integrated Radiology/Pathology Service for Breast Cancer and How It Changes Management of the Patient". **Invited Speaker, Molecular Summit, Philadelphia, Pennsylvania, Feb 10, 2009.**

"Integrated Radiology/Pathology Service for Breast Cancer and How It Changes Management of the Patient". **Invited Speaker, CLMA, Tampa, Florida, May 4, 2009.**

"Pathology and Radiology's Combined Future is Now at KU: How Integrated Breast Cancer Diagnostics are Improving Patient Care". **Invited Speaker, The Dark report Web seminar, Aug 19, 2009.**

"What Does a Pap Smear Have to Do with Telepathology?" **Invited Speaker, Pathology Visions 2009. Digital Pathology Solutions Conference. San Diego, California, Sept 13-15, 2009.**